Copyright
©The Author(s) 2022.
World J Clin Cases. Jan 14, 2022; 10(2): 485-491
Published online Jan 14, 2022. doi: 10.12998/wjcc.v10.i2.485
Published online Jan 14, 2022. doi: 10.12998/wjcc.v10.i2.485
Table 1 Molybdenum target X-ray and magnetic resonance imaging combined methodology examination conditions
| X-ray | Pathological result | Total | MRI | Pathological result | Total | Both | Pathological result | Total | |||
| + | - | + | - | + | - | ||||||
| + | 50 | 3 | 53 | + | 53 | 2 | 55 | + | 61 | 2 | 63 |
| - | 13 | 60 | 73 | - | 10 | 61 | 71 | - | 2 | 61 | 63 |
| Total | 63 | 63 | 126 | / | 63 | 63 | 126 | / | 63 | 63 | 126 |
Table 2 Molybdenum target X-ray and magnetic resonance imaging diagnostic efficacies
| Diagnostic method | Sensitivity | Specificity | Accuracy |
| Molybdenum target X-ray | 79.37% (50/63) | 95.24% (60/63) | 87.30% (110/126) |
| MRI | 84.13% (53/63) | 96.83% (61/63) | 90.48% (114/126) |
| Combined methodology | 96.83% (61/63) | 96.83% (61/63) | 96.83% (122/126) |
| χ2/P value (Combined vs molybdenum target X-ray) | 7.568/0.006 | 0.000/1.000 | 6.572/0.010 |
| χ2/P value (Combined vs MRI) | 4.513/0.034 | 0.262/0.609 | 4.271/0.039 |
Table 3 Magnetic resonance imaging-related examination parameters (mean ± SD)
| Group | T-wave peak | Apparent diffusion coefficient | Peak enhancement rate | Early enhancement rate |
| Breast cancer (n = 63) | 169.43 ± 32.05 | 1.01 ± 0.23 | 1.08 ± 0.24 | 1.07 ± 0.26 |
| Benign tumor (n = 63) | 228.86 ± 46.51 | 1.41 ± 0.35 | 0.83 ± 0.19 | 0.75 ± 0.19 |
| t value | 8.351 | 7.581 | 6.482 | 7.887 |
| P value | 0.000 | 0.000 | 0.000 | 0.000 |
- Citation: Gu WQ, Cai SM, Liu WD, Zhang Q, Shi Y, Du LJ. Combined molybdenum target X-ray and magnetic resonance imaging examinations improve breast cancer diagnostic efficacy. World J Clin Cases 2022; 10(2): 485-491
- URL: https://www.wjgnet.com/2307-8960/full/v10/i2/485.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i2.485